製藥業的授權協議：2021-2026年

利用基於 2,299個真實案例的交易資料，深入了解製藥業授權協議的結構、評估和談判機制。

本報告提供了全球製藥業宣布的2299 項許可協議的全面資訊。

許可授權是製藥公司利用外部創新、實現資產收益化、擴展開發平臺以及取得技術和產品權利的最重要手段之一。

本報告檢視了每家公司如何建構這些交易，哪些組織最活躍，授權活動集中在哪些地區，以及可以從揭露的財務條款和公開的合約文件中檢驗什麼。

這份報告不僅限於識別交易；它還為希望了解哪些權利被授予、資訊來源如何分擔、貨幣補償如何構建以及類似協議是如何實際談判的團隊提供了可操作的資訊和基準資源。

本報告目的是為參與評估、制定或談判藥品許可協議的業務發展、許可、研究和評估、公司策略、法律、合作夥伴關係管理和交易團隊提供參考。

了解製藥業的授權合約趨勢

本報告分析了2021年至2026年授權合約的以下幾個面向：

• 授權協議的年度趨勢
• 合作關係建立時的發展階段
• 產業部門
• 治療區域
• 技術類型
• 最積極參與許可協議的公司
• 基於公開揭露金額的主要授權協議
• 簽訂許可協議的策略原因
• 製藥公司授權策略的變化
• 能夠清楚地了解授權活動集中在哪些領域，以及哪些公司、技術和治療領域在合作方面最受關注。
• 了解許可協議的結構
• 許可協議必須謹慎分配權利、責任、經濟條款以及對許可資產和技術的未來控制權。

本報告提供以下資訊，幫助考慮以下事項：

• 授予的權利/保留的權利
• 獨家/非獨家許可
• 依地區/銷售區域分類的權利
• 應用領域的限制
• 發展責任
• 負責監理合規
• 關於製造和供應的協議
• 商業化方面的權利義務
• 智慧財產權所有權和管理
• 轉讓許可權
• 管治與決策
• 關於開發和商業化的實質審查
• 合約期限和終止條款
• 財務狀況（如公開資訊）
• 這些例子在評估許可協議的結構或準備談判時提供了有用的參考資訊。
• 對許可協議的財務條款進行基準分析
• 財務結構是醫藥業許可核准中極為重要的因素。

本報告提供與各項許可協議相關的已披露財務資訊，用戶可以查閱以下內容：

• 預付款
• 發展里程碑
• 監管里程碑
• 商業化里程碑
• 特許權使用費安排
• 股票投資
• 研發經費
• 已揭露的其他財務承諾
• 主要許可協議按披露的合約價值進行排名，使用戶能夠識別關鍵領先並研究其底層結構。
• 這些資訊可用於將提案合約與類似的實際合約進行比較，並為合約的準備和談判提供支援。
• 確定主要授權合約公司
• 本報告重點關注許可協議最活躍的前25 家公司，並分析在製藥業授權交易中積極主動的公司。

目錄

執行摘要

第1章 引言

第2章 授權協議的發展趨勢

• 許可協議的定義
• 授權協議的發展趨勢
  • 年度授權合約
  • 依開發階段授權合約
  • 產業特定授權合約
  • 依治療領域分類的授權合約
  • 依技術類型授權合約
  • 最活躍的公司特定授權合約
• 簽訂許可合作協議的原因
• 授權協議的未來

第3章 許可協議的結構：概述

• 許可協議的結構

第4章 主要授權協議

• 依合約金額分類的主要授權合約

第5章 最積極簽訂授權合約的25家公司

• 最積極簽訂授權合約的前25 家公司

第6章 授權合約目錄（包含合約）

• 可供審查的授權合約。
• 合約目錄
• 交易目錄：依公司（AZ）
• 交易目錄：依治療領域分類
• 交易目錄：依技術類型
• 關於生物製藥研究
• Current Partnering
• Current Agreements
• Current Partnering近期報告標題

Understand how pharmaceutical licensing deals are structured, valued and negotiated using intelligence from 2,299 real-world transactions.

Licensing Deals in Pharmaceuticals provides comprehensive intelligence on 2,299 licensing deals announced across the global pharmaceutical industry.

Licensing remains one of the most important mechanisms through which pharmaceutical companies access external innovation, monetize assets, expand development pipelines and secure rights to technologies and products.

The report examines how companies structure these transactions, which organizations are most active, where licensing activity is concentrated and what can be learned from disclosed financial terms and publicly available contract documents.

Rather than simply identifying transactions, the report provides a practical intelligence and benchmarking resource for teams seeking to understand what rights are being licensed, how responsibilities are divided, how financial consideration is structured and how comparable agreements have been negotiated in practice.

It is designed for business development, licensing, search and evaluation, corporate strategy, legal, alliance management and transaction teams involved in evaluating, structuring or negotiating pharmaceutical licensing agreements.

Understand the pharmaceutical licensing landscape

The report analyzes licensing dealmaking from 2021 to 2026, including:

• Trends in licensing dealmaking by year
• Phase of development at the time of partnering
• Industry sector
• Therapy area
• Technology type
• Most active licensing dealmakers
• Leading licensing deals by disclosed value
• Strategic reasons for entering licensing agreements
• How pharmaceutical licensing strategies are evolving
• This provides a clear view of where licensing activity is concentrated and which companies, technologies and therapeutic areas are attracting the greatest partnering attention.
• Understand how licensing agreements are structured
• Licensing agreements require careful allocation of rights, responsibilities, economics and future control of the licensed asset or technology.

The report provides intelligence to help users examine areas including:

• Rights granted or retained
• Exclusive and non-exclusive licenses
• Geographic and territorial rights
• Field-of-use restrictions
• Development responsibilities
• Regulatory responsibilities
• Manufacturing and supply arrangements
• Commercialization rights and obligations
• Intellectual property ownership and control
• Sublicensing rights
• Governance and decision-making
• Development and commercialization diligence
• Term and termination provisions
• Financial terms where disclosed
• These real-world examples provide useful reference points when evaluating potential licensing structures or preparing for negotiations.
• Benchmark licensing deal financials
• Financial structure is a critical component of pharmaceutical licensing.

The report provides access to disclosed financial information associated with individual licensing agreements, allowing users to investigate elements such as:

• Upfront payments
• Development milestones
• Regulatory milestones
• Commercial milestones
• Royalty arrangements
• Equity investments
• Research or development funding
• Other financial commitments where disclosed
• Leading licensing deals are also ranked by disclosed deal value, enabling users to identify significant precedent transactions and investigate their underlying structures.
• This intelligence can help place proposed transactions into the context of comparable real-world agreements and provide evidence to support deal preparation and negotiation.
• Identify leading licensing dealmakers
• The report profiles the Top 25 most active licensing dealmakers, providing insight into companies with a demonstrated appetite for pharmaceutical licensing transactions.

Individual transaction histories can help users understand:

• Which companies are actively licensing assets and technologies
• The therapeutic and technology areas attracting their interest
• The development stages at which they typically partner
• Previous transactions that may provide relevant comparables
• Potential partners for future licensing opportunities
• This makes the report particularly valuable for partner identification, search and evaluation and competitive intelligence.
• Learn from real-world licensing contracts
• Where publicly available, the report provides access to underlying licensing contract documents.

These agreements can reveal significantly more than headline announcements, allowing users to examine how companies have negotiated and documented important provisions including:

• Scope of license
• Exclusivity
• Territory and field
• Intellectual property rights
• Development obligations
• Sublicensing
• Manufacturing and commercialization rights
• Upfront and milestone payments
• Royalty provisions
• Termination and reversion rights
• For teams preparing for a licensing transaction, access to real agreement language provides valuable insight into how comparable provisions have been structured in practice.
• Comprehensive licensing deal directory
• The report includes a comprehensive directory of 2,299 pharmaceutical licensing deals, enabling users to identify transactions relevant to their own assets, technologies and partnering objectives.

Deals can be reviewed by:

• Company
• Therapy area
• Technology type
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable transactions, potential partners and relevant deal structures when preparing licensing strategies and negotiations.
• Search and Evaluation teams
• Identify companies with demonstrated interest in particular technologies, therapeutic areas and stages of development.
• Corporate and Portfolio Strategy teams
• Understand how pharmaceutical companies are using licensing to access innovation, build pipelines and expand into new areas.
• Legal and Transaction teams
• Review real agreement structures and publicly available contract language to support drafting, negotiation and due diligence.
• Alliance Management teams
• Understand how rights, responsibilities, governance and ongoing obligations have been structured across comparable licensing relationships.
• Competitive and Market Intelligence teams
• Track licensing activity by company, technology, therapy area and development phase to identify changing partnering priorities.
• Turn market-wide intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying licensing intelligence to the customer's own business, assets, technologies or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective licensing partners, competitor activity, deal structures, financial benchmarks, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

• 2.1. Introduction
• 2.2. Definition of licensing deal
• 2.3. Trends in licensing deals
  • 2.3.1. Licensing dealmaking by year
  • 2.3.2. Licensing dealmaking by phase of development
  • 2.3.3. Licensing dealmaking by industry sector
  • 2.3.4. Licensing dealmaking by therapy area
  • 2.3.5. Licensing dealmaking by technology type
  • 2.3.6. Licensing dealmaking by most active company
• 2.4. Reasons for entering into licensing partnering deals
• 2.5. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

• 3.1. Introduction
• 3.2. Licensing agreement structure

Chapter 4 - Leading licensing deals

• 4.1. Introduction
• 4.2. Top licensing deals by value

Chapter 5 - Top 25 most active licensing dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active licensing dealmakers

Chapter 6 - Licensing deals including contracts directory

• 6.1. Introduction
• 6.2. Licensing deals with contracts
• Deal directory
• Deal directory - licensing dealmaking by companies A-Z
• Deal directory - licensing dealmaking by therapy area
• Deal directory - licensing dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of licensing
• Figure 2: Trends in licensing deal announcements
• Figure 3: Licensing deals signed at each phase of development
• Figure 4: Licensing deals by industry sector
• Figure 5: Licensing deals by therapy area
• Figure 6: Licensing deals by technology type
• Figure 7: Top 25 most active licensing dealmakers
• Figure 8: Top licensing deals by value
• Figure 9: Most active licensing dealmakers